Monopar Therapeutics (NASDAQ:MNPR) Research Coverage Started at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I began coverage on shares of Monopar Therapeutics (NASDAQ:MNPRGet Rating) in a research note released on Monday, Benzinga reports. The brokerage issued a buy rating and a $24.00 price target on the stock.

Other equities research analysts have also issued research reports about the company. Brookline Capital Management reissued a buy rating on shares of Monopar Therapeutics in a research report on Monday, October 3rd. Maxim Group raised their target price on Monopar Therapeutics to $8.00 in a research report on Wednesday, November 16th. Finally, Roth Capital reissued a buy rating on shares of Monopar Therapeutics in a research report on Friday, December 9th.

Monopar Therapeutics Price Performance

MNPR stock opened at $3.22 on Monday. The firm has a market capitalization of $41.60 million, a P/E ratio of -3.98 and a beta of 0.89. The business’s 50-day moving average is $2.57 and its two-hundred day moving average is $2.22. Monopar Therapeutics has a 1 year low of $1.39 and a 1 year high of $4.88.

Monopar Therapeutics (NASDAQ:MNPRGet Rating) last posted its quarterly earnings results on Thursday, November 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. On average, analysts expect that Monopar Therapeutics will post -0.81 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Monopar Therapeutics stock. UBS Group AG increased its position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPRGet Rating) by 529.8% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,561 shares of the company’s stock after buying an additional 16,455 shares during the quarter. UBS Group AG owned about 0.16% of Monopar Therapeutics worth $45,000 as of its most recent SEC filing. 1.55% of the stock is owned by institutional investors.

Monopar Therapeutics Company Profile

(Get Rating)

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

See Also

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with's FREE daily email newsletter.